Understanding End-of-Life Care Among Adolescents, Young Adults with Cancer
the Cancer Therapy Advisor take:
Most adolescents and young adults (AYAs) with cancer received medically intensive end-of-life (EOL) care measures, according to an article published online in the journal JAMA Oncology.
The authors studied the health records of 663 AYAs who were diagnosed with either stage 1 to 3 cancer and evidence of recurrence or stage 4 cancer in the Kaiser Permanente Southern California (KSPC) registry. All patients died before the age of 40 (time of death age range, 15-39 years) between 2001 and 2010.
Results showed 72 (11%) out of the 663 patients were administered chemotherapy within 14 days of death. One hundred forty-four (22%) of AYAs were admitted to the intensive care unit, 147 (22%) visited the emergency department more than once, and 413 (62%) had a hospitalization in the last 30 days of life.
Furthermore, 449 of the 663 (68%) AYA patients with cancer received at least one medically intensive EOL care measure.
The study advocates for a better understanding of EOL care in the AYA population.
Most adolescents and young adults with cancer received medically intensive end-of-life care measures.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer